CDXS — Codexis, Inc.

Codexis (CDXS) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $15.2 million for Q1 2026, up from $7.5 million in Q1 2025, primarily due to revenue recognition from a Merck technology transfer agreement.
• Product Gross Margin: 71% in Q1 2026, compared to 55% in Q1 2025, driven by a favorable product mix.
• R&D Expenses: $11.4 million, down from $12.9 million in the prior year, reflecting lower allocable costs despite increased employee-related expenses.
• SG&A Expenses: $9.8 million, down from $12.4 million, due to reduced headcount and lower stock-based compensation.
• Net Loss: $8.7 million, improved from a loss of $20.7 million in Q1 2025.
• Cash Position: $65.1 million at the end of Q1 2026, down from $78.2 million at the end of 2025, expected to fund operations through the end of 2027.

2. Strategic Updates and Business Highlights

• Codexis is advancing its ECO Synthesis platform for RNA medicine production, addressing scalability and environmental impact in manufacturing.
• The company is preparing to present new data on its ECO Synthesis technology at the upcoming TIDES Conference, emphasizing advancements in stereochemical control of siRNA.
• The small molecule biocatalysis business remains stable, supporting 13 commercial products, including a recently approved HIV treatment in partnership with Merck.
• There are over 50 opportunities in the sales pipeline, with strong interest from 40 companies, indicating a robust demand for enzymatic production solutions.

3. Forward Guidance and Outlook

• Codexis maintains its revenue guidance for 2026, expecting total revenue between $72 million and $76 million, with a heavier weighting towards the second half of the year.
• The company is on track to achieve a half-kilogram scale for its ECO Synthesis platform by the end of 2026, with plans for a new GMP facility to be operational by the end of 2027.

4. Bad News, Challenges, or Points of Concern

• The decline in cash reserves from the previous quarter raises concerns about funding for ongoing projects and capital expenditures.
• The transition from small-scale to larger-scale production poses inherent risks, including process control challenges and the need for extensive validation as production scales up.
• The competitive landscape in RNA medicine manufacturing is intensifying, with increasing demand potentially outpacing current production capabilities.

5. Notable Q&A Insights

• Management highlighted the upcoming TIDES presentation, which will showcase new data on stereochemical control, a significant differentiator for their siRNA products.
• There are ongoing discussions with the FDA regarding the ECO Synthesis platform, with potential for faster approval timelines if the Advanced Manufacturing Technologies designation is achieved.
• The company is optimistic about securing new strategic partnerships by the end of 2026, with positive engagement from existing CDMO partnerships.
• The sales funnel includes a diverse mix of large pharma, biotech, and emerging biotech companies, indicating a broad interest in their technology across various market segments.

Overall, Codexis is positioned for growth in the RNA medicine space, with a strong focus on innovation and strategic partnerships, despite facing challenges related to scaling production and cash management.